PPARA and metabolic dysfunction-associated steatohepatitis: Another promising treatment entering phase III trials is Lanifibranor, a Pan-PPAR agonist which demonstrated a resolution of NASH without the worsening of fibrosis in 49% of those receiving the high dose relative to 22% in the placebo group [124,125].